Our subscribers speak for themselves:
“NeuroInvestment updates provide deep insight about the product development landscape across neuroscience diseases – far greater than any other source available. Harry is not afraid to provide strong opinions on the merits of new approaches to treating diseases, or of a company’s management, but these always supported by evidence, and subsequent events usually prove the judgement to have been accurate. And all this is provided in a unique style that makes for enjoyable reading – quite an achievement. There is nothing comparable that I am aware of in any other therapeutic area. People look forward to the start of a month – if I haven’t forwarded on the next copy of NeuroInvestment by the end of the first day, I always receive emails asking where it is!”
—Global Strategy Director, Neurosciences; A Top Five Pharma Company
"NeuroInvestment is informative, thoughtful, well researched, and refreshingly irreverent... a must read for individuals involved in the business of neuroscience."
—Chris Fibiger PhD, former head of neuroscience at Biovail, Amgen, Lilly
"Opinions are cheap; data is cheap. Opinions informed by data are rare and of enormous value. That's Harry Tracy and NI Research. He knows the neuro market like no one we've ever seen; he forms his opinions – often counterintuitive – using an extraordinary database of clinical and scientific understanding and the kind of analytical creativity that grabs truth where it's least expected. We see that both in the consulting work he does (a crackerjack job in defining the most important licensable compounds) and in his writing in NeuroPerspective: expert analysis and opinion, authoritatively and honestly derived.
—Roger Longman, Co-founder; Windhover Information
"Brilliant, timely, thoroughly researched, witty and always insightful. No morning note, scientific review article or thought leader interview can match this, in my opinion."
—Murali Doraiswamy MD, Director, Psychiatry Clinical Trials, Chief, Division of Biological Psychiatry, Duke University Medical Center
"I am delighted to recommend the newsletter, NeuroInvestment. It is extremely well-written, pithy, and informative. It provides a state-of-the-art review of a topic of relevance to neurotherapeutics each month. I have found it to be accurate and it is also a great source of information about new drugs under development. I am always impressed by how well-researched each topic is. Dr. Tracy is the Shakespeare of Neuroscience."
—Flint Beal MD PhD Chairman and Chief, Department of Neurology, Cornell Medical College
"Ferghana considers NeuroInvestment an extremely useful business intelligence tool, providing us with news and views on business, science and clinical topics in the complex field of neuroscience. In fact, we would like to find something similar in the other therapeutic sectors of interest to us...but NI is unique and thus greatly appreciated for its witty, insightful commentary and straightforward analyses."
—William J Kridel Jr, Managing Director, Ferghana Partners
"NeuroInvestment is on our absolutely must-read list. No other source gives such a complete and global view of the neuro space, including reviews that bring investors and biotech executives up to speed on key disease indications. NeuroInvestment is a no-nonsense review of all notable commercial efforts derived from the neurosciences, offering both comment and opinion. Dr. Tracy has created a brand product that defines the neuro investment space and keeps track of it. His report cards on companies go beyond what companies want you to know. NeuroInvestment is the conscience of commercial neuroscience, that is written as a service to investors, that educates the practitioners, and holds regulators and other shareholders accountable."
—Mark A. Cochran PhD, Managing Partner, NeuroVentures Fund